hCG with TRT

The testes do not run on their own. The hypothalamus releases GnRH, which tells the pituitary to send out LH and FSH, and those two signals drive the testes to make testosterone locally and to produce sperm. The system is a feedback loop: when testosterone in the blood is high, the brain reads that as enough and turns the signal down.

Testosterone from an injection or gel raises blood testosterone from the outside, so the loop reacts the same way - it suppresses the pituitary, LH and FSH drop, and the testes lose their input. A 2022 review in Therapeutic Advances in Urology describes the result as hypogonadotropic hypogonadism: diminished LH and FSH, and with it a fall in intratesticular testosterone. Because sperm production depends on that high local testosterone concentration inside the testes - far higher than the level in the blood - spermatogenesis is impaired, and the testes can shrink.

hCG is a placental hormone, but its structure lets it act on the same receptor as LH. The FDA label for Novarel puts it plainly: the action of hCG is virtually identical to that of pituitary LH, stimulating the Leydig cells of the testis to produce androgens. So when TRT has switched off the body's own LH, hCG can stand in for it - the testes keep getting a signal, and intratesticular testosterone is maintained even though the pituitary has gone quiet.

That mechanism is what a 2010 randomized trial demonstrated directly. Researchers used a GnRH antagonist to block gonadotropins in healthy men, mimicking the suppressed state, then gave very low doses of hCG. Even 60 to 125 IU every other day raised intratesticular testosterone well above placebo, dose-dependently - median intratesticular testosterone rose from roughly 77 nmol/L on placebo to about 987 nmol/L at the 125 IU dose. The point is not the exact numbers but the principle: a small LH-like signal from hCG restores the local testosterone that TRT removes.

Maintaining intratesticular testosterone is the reason hCG is paired with TRT when a man wants to protect sperm production. The 2022 review reports that concurrent hCG preserved intratesticular testosterone in men on testosterone (citing Coviello's alternate-day 250 and 500 IU arms), and that low-dose hCG at 500 IU preserved semen parameters in hypogonadal men on TRT (Hsieh). The community-cited range for this adjunct use is 250-500 IU subcutaneously two to three times a week, in line with those study doses.

This is reference context, not a target. Responses vary between men, fertility is affected by many things beyond a single hormone, and the decision to run hCG - and at what dose - belongs with a clinician who can check semen parameters and bloodwork. For the compound's own details and reconstitution, see the hCG reference page.

hCG's FDA-approved male indications are hypogonadotropic hypogonadism and prepubertal cryptorchidism. There is no approved indication for using it alongside testosterone to preserve the testes or fertility, so that use is off-label. The 2022 review notes the co-administration has been popularized as a strategy even though the AUA and EAU guidelines advise against TRT in men who are actively seeking fertility in the first place.

Off-label does not mean baseless - it means the mechanism and supporting studies exist, but a regulator has not signed off on this specific use, and it is not a substitute for individualized care. A separate path some men take is to avoid exogenous testosterone entirely and instead raise their own testosterone with a SERM that keeps LH and FSH switched on; the enclomiphene-for-fertility page covers that contrast. Which approach fits is a clinical decision, and nothing here is a recommendation to start, stop, or dose anything.